Activity of pyrazinamide in a murine model against Mycobacterium tuberculosis isolates with various levels of in vitro susceptibility

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 1, 1996, Pages 14-16

  Klemens, S P ^a,b   Sharpe, C A ^a   Cynamon, M H ^a  

^a SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^b State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PYRAZINAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; CONCENTRATION RESPONSE; DRUG EFFICACY; FEMALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; TUBERCULOSIS;

EID: 0030071473     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.1.14     Document Type: Article

References (22)

1. Bass, J. B., Jr., L. S. Farer, P. C. Hopewell, R. O'Brien, R. F. Jacobs, F. Ruben, D. E. Snider, Jr., and G. Thornton. 1994. Treatment of tuberculosis and tuberculosis infection in adults and children Am. J. Respir Crit. Care Med. 149:1359-1374.
2. Butler, W. R., and J. O. Kilburn. 1983 Susceptibility of Mycobacterium tuberculosis to pyrazinamide and its relationship to pyrazinamidase activity Antimicrob. Agents Chemother. 24:600-601.
3. Centers for Disease Control. 1991. Transmission of multidrug-resistant tuberculosis from an HIV-positive client in a residential substance-abuse facility - Michigan. Morbid. Mortal. Weekly Rep. 40:129-131.
4. Davidson, P. T., and H. Q. Le. 1992. Drug treatment of tuberculosis - 1992. Drugs 43:651-673.
5. Dessau, F. I., R. L. Yeager, and M. Kulish. 1952. Pyrazinamide (aldinamide) in experimental tuberculosis of the guinea pig. Am Rev. Tuberc. 65:519-522.
6. Ellard, G. A. 1969. Absorption, metabolism and excretion of pyrazinamide in man. Tubercle 50:144-158.
7. Fischl, M. A., G. L. Daikos, R. B. Uttamchandani, R. B. Poblete, J. N. Moreno, R. R. Reyes, A. M. Boota, L. M. Thompson, T. J. Cleary, S. A. Oldham, M. J, Saldana, and S. Lai. 1992. Clinical presentation and outcome of patients with HIV infection and tuberculosis caused by mtutiple-drug-resistant bacilli. Ann. Intern. Med. 117:184-190.
8. Grosset, J. 1978 The sterilizing value of rifampicin and pyrazinamide in experimental short course chemotherapy Tubercle 59:287-297.
9. Grosset, J. H. 1990. Present and new drug regimens in chemotherapy and chemoprophylaxis of tuberculosis Bull. Int Union Against Tuberc. Lung Dis. 65:86-91.
10. Heifets, L., B. 1991. Drug susceptibility tests in the management of chemotherapy of tuberculosis, p 109-114. In L. B. Heifets (ed.). Drug susceptibility in the chemotherapy of mycobacterial infections. CRC Press, Inc., Boca Raton. Fla.
11. Heifets, L. B., M. A. Flory, and P. J. Lindholm-Levy. 1989. Does pyrazinoic acid as an active moiety of pyrazinamide have specific activity against Mycobacterium tuberculosis? Antimicrob. Agents Chemother. 33:1252-1254
12. Kirk, R. E. 1986. Experimental design, procedures for the behavioral sciences. Brooks-Cole Publishing Co., Belmont. Calif.
13. Klemens, S. P., M. S. DeStefano, and M. H. Cynamon. 1993. Therapy of multidrug-resistant tuberculosis: lessons from studies with mice. Antimicrob. Agents Chemother. 37:2344-2347.
14. Konno, K., F. M. Feldmann, and W. McDermott. 1967 Pyrazinamide susceptibility and amidase activity of tubercle bacilli. Am. Rev. Respir. Dis. 95:461-469.
15. Lecoeur, H. F., C. Truffot-Pernot, and J. H. Grosset 1989. Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide. Am. Rev. Respir. Dis. 140:1189-1193.
16. Mackaness, G. B. 1956. The intracellular activation of pyrazinamide and nicotinamide. Am. Rev. Tuberc. 74:718-728.
17. Malone, L., A. Schurr, H. Lindh, D. McKenzie, J. S. Kiser, and J. H. Williams. 1952. The effect of pyrazinamide (aldinamide) on experimental tuberculosis in mice Am Rev. Respir. Dis. 65:511-518.
18. McClatchy, J. K., A. Y. Tsang, and M. S. Cernich. 1981. Use of pyrazmamidase activity in Mycobacterium tuberculosis as a rapid method for determination of pyrazinamide susceptibility. Antimicrob. Agents Chemother 20: 556-557.
19. McDermott, W., and R. Tompsett. 1954. Activation of pyrazinamide and nicotinamide in acidic environments in vitro. Am. Rev. Tuberc. 70:748-754.
20. Pearson, M. L., J. A. Jereb, T. R. Frieden, J. T. Crawford, B. J. Davis, S. W. Dooley, and W. R. Jarvis. 1992. Nosocomial transmission of multidrug-resistant Mycobacterium tuberculosis: a risk to patients and health care workers. Ann. Intern. Med. 117:191-196.
21. Vestal, A. L. 1969. Procedures for the isolation and identification of mycobacteria. Public Health Service publication no. 1995, p. 113-115. Laboratory Division, National Communicable Disease Center, Atlanta.
22. Yeager, R. L., W. G. C. Munroe, and F. I. Dessau. 1952. Pyrazinamide (aldinamide) in the treatment of pulmonary tuberculosis. Am. Rev. Tuberc. 65:523-546.